H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Mainz Biomed to $7 from $10 and keeps a Buy rating on the shares post the Q2 report. The company reported an earnings miss in Q2 but clinical catalysts are forthcoming, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
- Mainz Biomed launches ColoAlert with Marylebone Laboratory in the UK
- Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
- Mainz Biomed enters commercial partnership with Fugene Genetics for ColoAlert
- Mainz Biomed Announces Collaboration with Fugene Genetics in Israel